Skip to main content

Safety and efficacy of dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial

The findings from the EDCTP-funded MAMAH trial, which was conducted between 2019 and 2023 in 5 sites in semi-rural areas in Gabon and Mozambique, showed that dihydroartemisinin-piperaquine (DHA-PPQ) as malaria intermittent preventive treatment during pregnancy (IPTp) administered concomitantly with prophylactic co-trimoxazole in pregnant women living with HIV is safe and reduces the risk of clinical malaria and overall Plasmodium falciparum infection.

The article which was published in January 2024 in The Lancet Infectious Diseases, highlights the potential of DHA-PPQ as a safe and effective strategy for malaria prevention in pregnant women living with HIV. An announcement of the article is available on the EDCTP website.